Induction of the remission of immune thrombocytopenic purpura
- Authors: Odin V.I.1, Lehthlaan-Thynisson N.P.2, Zolotarev A.D.1, Mineeva N.V.3, Polyakov A.S.1
-
Affiliations:
- Military medical academy of S.M. Kirov
- Scientific and Practical Institute for Advanced Medicine
- Russian Research Institute of Hematology and Transfusiology
- Issue: Vol 22, No 3 (2020)
- Pages: 93-98
- Section: Clinical trials
- URL: https://journals.rcsi.science/1682-7392/article/view/50541
- DOI: https://doi.org/10.17816/brmma50541
- ID: 50541
Cite item
Abstract
Abstract. A review of the literature on remission of immune thrombocytopenic purpura in children and a retrospective analysis of its course in a young patient who was successively applied, first to no avail, standard drug therapy, and then, due to the lack of effect, a physiotherapy technique based on the principles of activation therapy. It is known that immune thrombocytopenic purpura is a rare acquired autoimmune disease characterized by isolated thrombocytopenia with the occurrence of hemorrhagic syndrome of varying severity, which can lead to fatal bleeding. At the same time, antiplatelet antibodies are detected only in half of patients suffering from immune thrombocytopenic purpura, and therefore are not a necessary criterion for diagnosis, which in turn makes it difficult to diagnose the disease and does not allow them to be used as a criterion for the effectiveness of treatment. Despite the fact that in childhood, most cases of immune thrombocytopenic purpura occur in acute form, often with the development of spontaneous remission, but in a significant part of patients, relapses of the disease are accompanied by significant thrombocytopenia, hemorrhagic syndrome, and a decrease in the quality of life, which requires specific therapy up to splenectomy. When using the Reverse wave technique in the treatment of immune thrombocytopenic purpura, a stable, long-term remission was achieved in a young patient. The prospects of studying the application of this physiotherapy technique in clinical practice are discussed.
Full Text
##article.viewOnOriginalSite##About the authors
V. I. Odin
Military medical academy of S.M. Kirov
Author for correspondence.
Email: vmeda-nio@mail.ru
Russian Federation, Saint Petersburg
N. P. Lehthlaan-Thynisson
Scientific and Practical Institute for Advanced Medicine
Email: vmeda-nio@mail.ru
Russian Federation, Saint Petersburg
A. D. Zolotarev
Military medical academy of S.M. Kirov
Email: vmeda-nio@mail.ru
Russian Federation, Saint Petersburg
N. V. Mineeva
Russian Research Institute of Hematology and Transfusiology
Email: vmeda-nio@mail.ru
Russian Federation, Saint Petersburg
A. S. Polyakov
Military medical academy of S.M. Kirov
Email: vmeda-nio@mail.ru
Russian Federation, Saint Petersburg
References
- Богданов, А.Н. Изменения системы крови при ревматических заболеваниях / А.Н. Богданов [и др.] // Вестн. Росс. воен.-мед. акад. – 2013. – № 2 (42). – С. 173–179.
- Галль, Л.Н. Физические принципы функционирования материи живого организма / Л.Н. Галль. – СПб.: Изд.-во Политехнического университета, 2014. – 400 с.
- Гаркави, Л.Х. Антистрессорные реакции и активационная терапия / Л.Х. Гаркави, Е.Б. Квакина, Т.С. Кузьменко. – М.: ИМЕДИС, 1998. – 655 с.
- Довгуша, В.В. Вода – привычная и парадоксальная / В.В. Довгуша, Н.П. Лехтлаан-Тыниссон, Л.В. Довгуша. – СПб., 2007. – 242 с.
- Лисуков, И.А. Иммунная тромбоцитопения: клинические проявления и ответ на терапию. Промежуточный анализ данных Российского регистра пациентов с первичной иммунной тромбоцитопенией и обзор литературы / И.А. Лисуков [и др.] // Онкогематология. – 2013. – № 2 (8). – С. 61–69.
- Меликян, А.Л. Дифференциальная диагностика тромбоцитопений / А.Л. Меликян [и др.] // Онкогематология. – 2017. – № 1 (12). – С. 78–87.
- Свидетельство на товарный знак № 3382672 «Обратная волна». Правоообладатель: ООО «Научно-практический Институт перспективной медицины». Заявка № 2008707474. Приоритет тов. знака 14 марта 2008 г. Зарег. в Гос. реестре тов. знаков и знаков обсл. РФ 01 июля 2009 г.
- Abrahamson, P.E. The incidence of idiopathic thrombocytopenic purpura (ITP) among adults: a population-based study and literature review / P.E. Abrahamson [et al.] // European Journal of Hematology. – 2009. – № 2 (83). – P. 83–89.
- Bennett, C.M. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants / С. М. Bennett [et al.] // Pediatric Blood & Cancer. – 2018. – № 1 (65). – P. 1–7.
- Cooper, N. Immune Thrombocytopenia / N. Cooper // New England Journal of Medicine. – № 10 (381). – P. 945–955.
- Cooper, N. The child with immune thrombocytopenia: to treat or not to treat, is that still the question? / N.Cooper [et al.] //Haematologica. – 2019. – № 11 (104). – P. 2132–2134.
- De Mattia, D. Management of Chronic Childhood Immune Thrombocytopenic Purpura: AIEOP Consensus Guidelines / D. De Mattia [et al.] // Acta Haematologica. – 2010. – № 2 (123). – P. 96–109.
- Doobaree, I.U. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry / I.U. Doobaree [et al.] // European Journal of Hematology. – 2019. – № 5 (102). – P. 416– 423.
- Fogarty, P.F. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation / P.F. Fogarty // Hematology/Oncology Clinics of North America. – 2009. – № 6 (23). – P. 1213–1221.
- Jayabose, S. Long-Term Outcome of Chronic Idiopathic Thrombocytopenic Purpura in Children / S. Jayabose [et al.] // Journal of Pediatric Hematology/Oncology. – 2004. – № 11 (26). – P. 724–726.
- Lee, A.C. Isolated thrombocytopenia in childhood: what if it is not immune thrombocytopenia? / A.C. Lee // Singapore Medical Journal. – 2018. – № 7 (59). – P. 390–393.
- Li, J. Pathophysiology of immunethrombocytopenia / J. Li [et al.] // Current Opinion in Hematology. – 2018. – № 5 (25). – P. 373–381.
- Michel, M. Immune thrombocytopenic purpura: epidemiology and implications for patients / M. Michel //European Journal of Hematology. – 2009. – № s71 (82). – P. 3–7.
- Neunert, C.E. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS) / C.E. Neunert [et al.] // Blood. – 2013. – № 22 (121). – P. 4457–4462.
- Semple, J.W. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet Tcell reactivity / J.W. Semple [et al.] // Blood. – 1996. – № 10 (87). – P. 4245–4254.
- Tarantino, M.D. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia / M.D. Tarantino [et al.] // Haematologica. – 2019. –№ 11 (104). – P. 2283–2291.
- Zainal, A. Immune thrombocytopenic purpura / A. Zainal [et al.] // Journal of community hospital internal medicine perspectives. – 2019. – № 1 (9). – P. 59–61.